165 related articles for article (PubMed ID: 37674806)
1. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol.
Lee V; Zheng Q; Toh DF; Pua CJ; Bryant JA; Lee CH; Cook SA; Butler J; Díez J; Richards AM; Le TT; Chin CWL
Front Cardiovasc Med; 2023; 10():1248468. PubMed ID: 37674806
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
Diao K; Wang D; Chen Z; Wu X; Ma M; Zhu Y; Zhang L; Wang H; Wang M; He S; Li C; Deng Q; Yan T; Wu T; Tang L; Huang B; Sun J; He Y
Clin Cardiol; 2021 Dec; 44(12):1709-1717. PubMed ID: 34668596
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Ledwidge M; Dodd JD; Ryan F; Sweeney C; McDonald K; Fox R; Shorten E; Zhou S; Watson C; Gallagher J; McVeigh N; Murphy DJ; McDonald K
JAMA Cardiol; 2023 Apr; 8(4):366-375. PubMed ID: 36884247
[TBL] [Abstract][Full Text] [Related]
4. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
[TBL] [Abstract][Full Text] [Related]
5. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Kario K
Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
7. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S
Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651
[TBL] [Abstract][Full Text] [Related]
8. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
[TBL] [Abstract][Full Text] [Related]
9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
Codina P; Domingo M; Barceló E; Gastelurrutia P; Casquete D; Vila J; Abdul-Jawad Altisent O; Spitaleri G; Cediel G; Santiago-Vacas E; Zamora E; Ruiz-Cueto M; Santesmases J; de la Espriella R; Pascual-Figal DA; Nuñez J; Lupón J; Bayes-Genis A
ESC Heart Fail; 2022 Aug; 9(4):2170-2180. PubMed ID: 35588235
[TBL] [Abstract][Full Text] [Related]
11. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
[TBL] [Abstract][Full Text] [Related]
12. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
13. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
Mehran R; Steg PG; Pfeffer MA; Jering K; Claggett B; Lewis EF; Granger C; Køber L; Maggioni A; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Ducrocq G; Berwanger O; De Pasquale CG; Landmesser U; Petrie M; Leng DSK; van der Meer P; Lefkowitz M; Zhou Y; Braunwald E
Circulation; 2022 Dec; 146(23):1749-1757. PubMed ID: 36321459
[TBL] [Abstract][Full Text] [Related]
16. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis.
Yang P; Han Y; Lian C; Wu X
Front Cardiovasc Med; 2022; 9():988117. PubMed ID: 36093128
[TBL] [Abstract][Full Text] [Related]
18. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
[TBL] [Abstract][Full Text] [Related]
19. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
20. Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction.
Yang P; Li X; Wang L; Wu X; Wang C; Li T; Wang H
Front Cardiovasc Med; 2022; 9():1059420. PubMed ID: 36712243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
